Immune checkpoints act as homeostatic regulators of the immune system, and are crucial for maintaining immune tolerance. In tumor microenvironment (TME), tumor cells “hijack” the inhibitory mechanisms to avoid being eliminate. Immunotherapeutics that block these checkpoints have marked a revolution in the treatment of cancer and immunological diseases.
Creative Biolabs offers immune checkpoint inhibitor preclinical development services, covering antibodies, small molecule compounds, and peptides.
- Immune Checkpoint Inhibitors, The Next Generation Cancer Therapy - Creative Biolabs ( Download)
- Cancer Immune Checkpoint Inhibitors ( Download)
- Immune Checkpoints: Targeting TIGIT ( Download)
- Introduction to Immune Checkpoint Inhibitor (ICI) Immunotherapy ( Download)
- Macrophages as Targets in Cancer Immunotherapy - Creative Biolabs ( Download)
- Immunotherapy using checkpoint inhibitors (subtitles) ( Download)
- Liposomal Delivery Systems in Cancer Therapy - Creative Biolabs ( Download)
- What are Immune Checkpoints ( Download)
- Immune Checkpoint Inhibitors ( Download)
- A snapshot of Creative Biolabs' highlights from the 10th Immuno-Oncology Summit ( Download)
- Immune checkpoint inhibitors: recent progress and potential biomarkers - 2i Immune Cells ( Download)
- Immune checkpoint inhibitors: recent progress and potential biomarkers - 1i Introduction ( Download)
- Immune checkpoint inhibitors: recent progress and potential biomarkers - 1v Introduction ( Download)
- Immune checkpoint inhibitors: recent progress and potential biomarkers - 1iv Introduction ( Download)
- Immune checkpoint inhibitors: recent progress and potential biomarkers - 6iii Epigenetic Signatures ( Download)
